Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Mirtazapine is an antidepressant medication prescribed for major depression, including helping to prevent depression from returning after treatment. It works by blocking certain receptor sites in the brain, which leads to increased release of noradrenaline and serotonin—two chemical messengers involved in mood regulation. The released serotonin then acts on specific receptors (called 5-HT1 receptors) because mirtazapine blocks other serotonin receptors (5-HT2 and 5-HT3) at the same time.
The medication stays active in the body for 20 to 40 hours after a dose, though this can vary—occasionally up to 65 hours in some people, and sometimes shorter periods in young men. Mirtazapine is broken down in the liver by several enzymes (CYP 2D6, CYP 1A2, and CYP 3A4), which means other medications that affect these enzymes could change how mirtazapine works in the body.
Side effects your family member might experience include drowsiness or sedation, especially during the first few weeks of treatment. They may also feel dizzy, develop headaches, notice an increase in appetite, or gain weight. These are effects that doctors know to watch for when someone starts taking mirtazapine.
More serious side effects are possible but require immediate medical attention. These include agranulocytosis (a severe drop in white blood cells that affects the body's ability to fight infection), suicidal thoughts or behaviour, Stevens-Johnson syndrome (a severe skin reaction), and serotonin syndrome (which can happen when too much serotonin builds up in the body). If you notice any sudden changes in mood, unusual skin reactions, signs of infection, or other concerning symptoms, contact your family member's doctor straight away.
Mirtazapine should not be taken by anyone allergic to it or its ingredients, and it must not be combined with a class of antidepressants called MAO inhibitors. There needs to be at least 14 days between stopping one of these medications and starting the other.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · ObservationMajor depressive disorders Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
“Mirtazapine is an antagonist of central α2-auto and hetero-adrenoceptors which causes an increase in both noradrenaline and serotonin release. The effect of released serotonin is exerted specifically via 5-HT1 type receptors, because 5-HT2 and 5-HT3 type receptors are specifically blocked by mirtazapine.”
“The half-life of elimination ranged from 20-40 hours; longer half-lives, up to 65 hours, have occasionally been recorded and shorter half-lives have been seen in young men.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Mirtazapine is a tetracyclic piperazine-azepine antidepressant that antagonises central α₂-adrenoceptors, increasing noradrenaline and serotonergic neurotransmission. The released serotonin acts specifically via 5-HT₁ receptors; mirtazapine blocks 5-HT₂ and 5-HT₃ receptors directly. It is indicated for the treatment of major depressive disorder, including relapse prevention. The elimination half-life typically ranges from 20 to 40 hours, though values up to 65 hours have occasionally been recorded and shorter half-lives seen in young men.
Metabolism proceeds via CYP2D6 and CYP1A2 to the 8-hydroxy metabolite, and via CYP3A4 to N-demethyl and N-oxide metabolites. Concomitant use with monoamine oxidase inhibitors is contraindicated; a 14-day washout is recommended when switching to or from a MAOI. Common adverse effects include sedation (usually prominent during the first weeks), dizziness, headache, increased appetite, and weight gain. Serious adverse effects include agranulocytosis, suicidal ideation and behaviour, Stevens–Johnson syndrome, and serotonin syndrome. Mirtazapine is contraindicated in patients with hypersensitivity to the active substance or excipients.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“In vitro data from human liver microsomes indicate that cytochrome P450 enzymes CYP 2D6 and CYP 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas CYP 3A4 is considered to be responsible for the formation of the N-demethyl and N-oxide metabolites.”